NeuroQuest has become the first company to enter the state through SCRA investment and the first as a direct result of the S.C.-Israel Economic Development Mission. NeuroQuest, currently operating in Israel, has established its U.S. subsidiary and clinical development center at the Roper St. Francis Clinical Biotechnology Research Institute in Charleston. The company's local. development center will serve as the base for its clinical and regulatory work.
NeuroQuest testing of at-risk patients for Alzheimer’s and ALS is expected to open the window to treatment option that may slow and possibly reverse the effects of these diseases.
SC Launch and SCRA Technology Ventures are presenting a $450,000 check to NeuroQuest today during a networking event at the new Roper St. Francis Clinical Biotechnology Research Institute.